1 / 1

D ’ après Astrup et al., Int J Obes 2011;doi/10.1038/ijo.2011.158

Variation du poids entre l ’ inclusion et 2 ans de suivi. Orlistat 120 mg 3 x/j Placebo. Liraglutide 1,2 mg Liraglutide 1,8 mg. Liraglutide 2,4 mg Liraglutide 3,0 mg. 2. n = 356. n = 561. n = 526. n = 268. 0.

malinda-drakos
Download Presentation

D ’ après Astrup et al., Int J Obes 2011;doi/10.1038/ijo.2011.158

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Variation du poids entre l’inclusion et 2 ans de suivi Orlistat 120 mg 3 x/j Placebo Liraglutide 1,2 mg Liraglutide 1,8 mg Liraglutide 2,4 mg Liraglutide 3,0 mg 2 n = 356 n = 561 n = 526 n = 268 0 Tous les patients sous liraglutide/placebo ont reçu du liraglutide 2,4 mg à partir de S52, puis 3 mg entre S70 et S96 -2 -4 Perte de poids moyenne(kg) À partir du screening -6 -6,7 kg -8 -8,8 kg -9,4 kg -9,4 kg -9,9 kg -10,3 kg -10 Randomisation -12 Screening -14 104 0 96 -4 68 20 52 Semaines D’après Astrup et al., Int J Obes 2011;doi/10.1038/ijo.2011.158

More Related